Economic assessment of screening for pre-eclampsia

Prenatal Diagnosis

Volumn 32, Issue 1, 2012, Pages 29-38

  Shmueli, Amir ^a   Meiri, Hamutal ^b,d   Gonen, Ron ^c  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b Diagnostic Technologies   (Israel)

^c BNAI ZION MEDICAL CENTER   (Israel)

^d TeleMarpeh Ltd   (Israel)

Author keywords

Diabetes; Doppler; Early and late pre eclampsia; PIGF; PP13; QALY

Indexed keywords

PLACENTA PROTEIN; PLACENTAL GROWTH FACTOR; PLACENTAL PROTEIN 13; UNCLASSIFIED DRUG;

ARTICLE; CALCULATION; CHILD DEATH; DELIVERY; DOPPLER ECHOGRAPHY; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; NEWBORN DEATH; PREECLAMPSIA; PREGNANCY OUTCOME; PRENATAL SCREENING; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; UTERINE ARTERY;

ADULT; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DIAGNOSTIC TESTS, ROUTINE; FEMALE; HEALTH CARE COSTS; HUMANS; MODELS, THEORETICAL; PRE-ECLAMPSIA; PREGNANCY; PRIMARY PREVENTION;

EID: 84857505893     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.2871     Document Type: Article

References (48)

1. Clark SL, Belfort MA, Dildy GA, et al. Maternal death in the 21st century: causes, prevention, and relationship to cesarean delivery. Am J Obstet Gynecol 2008; 199: 36.e1-e5.
2. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet 2001; 357: 53-6.
3. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005; 308: 1592-4.
4. von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy 2003; 22: 143-8.
5. Altman D, Carroli G, Duley L, et al. Magpie Trial Collaboration Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002; 359: 1877-90.
6. Perez-Cuevas R, Fraser W, Reyes H, et al. Critical pathways for the management of preeclampsia and severe preeclampsia in institutionalised health care settings. BMC Pregnancy Childbirth 2003; 3: 6-10.
7. Koonin LM, MacKay AP, Berg CJ, et al. Pregnancy-related mortality surveillance--United States, 1987-1990. MMWR CDC Surveill Summ 1997; 46: 17-36.
8. Mathers CD, Lopez AD, Murray CJL. The Global Burden of Disease and Mortality by Condition: Data, Methods, and Results for 2001. In Global Burden of Disease and Risk Factors. Lopez AD, Mathers CD, Ezzati M, et al., (eds): World Bank. New York: Oxford University Press: Washington (DC) 2006; 45-93.
9. McDonald SD, Malinowski A, Zhou Q, et al. Cardiovascular sequleae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J 2008; 156: 918-30.
10. Libby G, Murphy DG, McEwan NF, et al. Preeclampsia and later development of type 2 diabetes in mothers and their children an intergenerational study from the Walker Cohort. Diabetologia 2007; 50: 523-30.
11. Geelhoed JJM, Fraser A, Tilling K, et al. Preeclampsia and gestational hypertension are Associated with childhood blood pressure independently of family adiposity measures. The Avon longitudinal study of parents and children. Circulation 2010; 122: 1192-9.
12. Poston L, Briley AL, Seed PT, et al. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet 2006; 367: 1145-54.
13. Xu H, Perez-Cuevas R, Xiong X, et al. An international trial of antioxidants in the prevention of preeclampsia (INTAPP). Am J Obstet Gynecol 2010; 202239: e1-10.
14. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. (on behalf of the PARIS Collaborative Group). Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 369: 1791-8.
15. Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev Aug 2010; 4(8): CD001059. Update of: Cochrane Database Syst Rev. 2006;3:CD001059.
16. Nilsen RM, Vollset SE, Rasmussen SA, et al. Folic acid and multivitamin supplement use and risk of placental abruption: A population-based registry study. Am J Epidemiol 2008; 167: 867-74.
17. Triche EW, Grosso LM, Belanger K, et al. Chocolate consumption in pregnancy and reduced likelihood of preeclampsia. Epidemiology 2008; 19: 459-64.
18. Haugen M, Brantsaeter AL, Trogstad L, et al. Vitamin D Supplementation and Reduced Risk of Preeclampsia in Nulliparous Women. Epidemiology 2009; 20: 720-6.
19. Qiu C, Coughlin KB, Frederick IO, et al. 2008. Dietary fiber intake in early pregnancy and risk of subsequent preeclampsia. Am J Hypertens 21: 903-9.
20. Bujold E, Roberge S, Lacass Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy. A meta-analysis. Obstet Gynecol 2010; 116: 402-14.
21. Conde-Agudelo A, Romero R, Lindheimer MD. Tests to Predict Preeclampsia. In: Chesley's Hypertensive Disorders in Pregnancy (3rd edn.) Lindheimer MD, Roberts JM, Cunningham FG. (eds.) Chesley LC, Academic Press: Amsterdam; 2009; 191-214.
22. Giguère Y, Charland M, Bujold E, et al. Combining Biochemical and Ultrasonographic Markers in Predicting Preeclampsia: A Systematic Review. Clin Chem 2010; 56: 361-75.
23. Cetin I, Huppertz B, Burton G, et al. Pregenesys pre-eclampsia markers a consensus meeting: what do we require from markers, risk assessment and model systems to tailor preventive strategies? Placenta 2011; 32(S1): S4-S16.
24. Romero R, Kusanovic JP, Than NG, et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol 2008; 199(122): e1-e11.
25. Gonen R, Shahar R, Grimpel YI, et al. Placental protein 13 as an early marker for pre-eclampsia: a prospective longitudinal study. BJOG 2010; 115: 1465-72.
26. Spencer K, Cowans NJ, Nicolaides KH. Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia. Prenat Diagn 2008; 28: 7-10.
27. Wortelboer, EJ, Koster, MPH, Cuckle HS, et al. First-trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early-onset pre-eclampsia. BJOG 2010; 117: 1384-9.
28. Spencer K, Cowans NJ, Chefetz I, et al. First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia. Ultrasound Obstet Gynecol 2007; 29: 128-34.
29. Akolekar R, Syngelaki S, Sarquis R, et al. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn 2011; 31: 66-74.
30. Khalil A, Cowans NJ, Spencer K, et al. First trimester markers for the prediction of preeclampsia in women with a-priori high risk. Ultrasound Obstet Gynecol 2010; 35: 671-9.
31. Cuckle H. Screening for pre-eclampsia - lessons from aneuploidy screening PlacentaSupplement Early Non-Invasive Markers. Placenta. 2011; 32S1: S42-S48.
32. Marlow N, Wolke D, Bracewell MA, Samara M. EPICure Study Group: Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med 2005; 352: 9-19.
33. Fanaroff AA, Stoll BJ, Wright LL, et al. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol 2007; 196: 147.e1-e8.
34. Chodick G, Porath A, Alapi H, et al. The direct medical cost of cardiovascular diseases, hypertension, diabetes, cancer, pregnancy and female infertility in a large HMO in Israel. Health Policy 2010; 95: 271-6.
35. Calderon-Margalit R, Friedlander Y, Yanetz R, et al. Late stillbirths and long-term mortality of mothers. Obstet Gynecol 2007; 109: 1301-8.
36. Calderon-Margalit R, Friedlander Y, Manor O, et al. Cardiovascular health of mothers and offspring following pregnancies complicated with preeclampsia. The Israel Medical Association Society for research, prevention and treatment of atherosclerosis conference, Eilat, October 2010.
37. Tsadok MA, Friedlander Y, Paltiel O, et al. A. J Obstet. Gynecol 2008; 199(6): SUPP/A: S33
38. Lindheimer MD, Taler SJ, Cunningham FG. American Society of Hypertension position paper: hypertension in pregnancy.Clin Hypertens (Greenwich 2009; 11: 214-25.
39. Israel Central Bureau of Statistics. Annuals Reports for 2005-2008, Jerusalem, Israel.
40. Harlap S, Davies AM, Deutsch L, et al. The Jerusalem Perinatal Study cohort, 1964-2005: methods and a review of the main results. Paediatr Perinat Epidemiol 2007; 21: 256-73.
41. Matusevitch A. An economic evaluation of physical activity and implications for its promotion, MPH thesis, The Hebrew University School of Public Health, January 2010.
42. nd ed. 2005.
43. Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: How are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7: 518-28.
44. Nicolaides KH. A model for a new pyramid of prenatal care based on the 11 to 13weeks' assessment. Prenat Diagn 2011; 31: 3-6.
45. Hadker N, Garg S, Costanzo C, et al. Financial impact of a novel preeclampsia diagnosis test versus standard practice: a decision-anlytical modeling analysis from a UK healthcare payer perspective. J Med Econ 2010; 13: 728-37.
46. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-83.
47. Simon J, Gray A, Duley LMagpie Trial collaborative group. Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Magpie Trial.BJOG 2006; 113: 144-51.
48. Meads CA, Cnossen JS, Meher S, et al. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess 2008; 12: 5-285.